AstraZeneca ($AZN) is in the midst of transferring its global R&D base to a $500 million campus in Cambridge, U.K., shouldering up with the famed institution in hopes of replicating other companies' successes in biotech hubs and jump-starting its pipeline. As R&D decisionmaker Menelas Pangalos tells The Wall Street Journal, the transition has been difficult, disrupting projects and stretching resources, but the company believes it'll be better suited in a collaborative research environment rather than the remote village that houses its current development operation. More (sub. req.)